Zobrazeno 1 - 10
of 601
pro vyhledávání: '"Portal vein tumor thrombosis"'
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 4, Pp 659-662 (2024)
Externí odkaz:
https://doaj.org/article/3a2507202e5f4ea6bf06b7843fd55880
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-11 (2024)
Abstract Background and objectives The purpose of this study was to investigate the survival benefit of Stereotactic Body Radiotherapy (SBRT) versus lenvatinib as first-line therapy in the treatment of hepatocellular carcinoma (HCC) with portal vein
Externí odkaz:
https://doaj.org/article/de863632ee2f45a1ba5373051ef84d51
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-14 (2024)
Abstract Background Portal vein tumor thrombosis (PVTT) commonly occurs in patients with primary liver cancer (PLC). Transarterial chemoembolization (TACE) is a treatment for patients with PLC and PVTT. Some studies have shown that combining TACE the
Externí odkaz:
https://doaj.org/article/d54e55f5d69a4a8297c7b30bd2902f85
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Portal vein tumor thrombosis (PVTT) is one of the common complications of HCC and represents a sign of poor prognosis. PVTT signifies advanced liver cancer, deteriorating liver function, and heightened susceptibility to intrahepatic dissemin
Externí odkaz:
https://doaj.org/article/a3bcd144e11a4f2289f75a70919365f1
Publikováno v:
Liver Research, Vol 8, Iss 3, Pp 141-151 (2024)
Hepatocellular carcinoma (HCC) is the sixth most prevalent form of cancer globally and the third leading cause of cancer-related mortality. The incidence of portal vein tumor thrombosis (PVTT) in HCC patients is 21% at one year and 46% at three years
Externí odkaz:
https://doaj.org/article/0a485adec1b34749b96133a23bf52e4f
Publikováno v:
Acta Pharmaceutica, Vol 74, Iss 3, Pp 405-422 (2024)
This meta-analysis aimed to evaluate the efficacy of sorafenib plus transcatheter arterial chemoembolization (TACE) in treating hepato-cellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Twelve randomized controlled trials published un
Externí odkaz:
https://doaj.org/article/65171b47ae0f4d4e8fc492e3a441eec1
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1581-1595 (2024)
Guimin Hou,1,* Feng Zhang,1,* Xielin Feng,1 Yan Chen,2 Jinliang Zhang,1 Haiqing Wang1 1Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospita
Externí odkaz:
https://doaj.org/article/d166c332658e4c0782cd2ebe1f593abe
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1473-1479 (2024)
Qi-Feng Chen,1,* Xiong-Ying Jiang,1,2,* Yue Hu,1,* Song Chen,1 Jun-Zhe Yi,1 Sui-Xing Zhong,1 Jiong-Liang Wang,1 Ning Lyu,1 Ming Zhao1 1Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, State Ke
Externí odkaz:
https://doaj.org/article/422b821a6bd645ca83e5b80b895c841c
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundHepatocellular carcinoma (HCC) patients exhibiting portal vein tumor thrombosis (PVTT) face a high risk of rapid malignant progression and poor outcomes, with this issue being compounded by a lack of effective treatment options. The integra
Externí odkaz:
https://doaj.org/article/fc51b26796a243b38f0fe912a7aaf7a8
Autor:
Feifei Mao, Yuqiang Cheng, Kang Wang, Zongtao Chai, Lei Guo, Yanyan Xu, Xue Chen, Jie Shi, Weixing Guo, Junling Liu, Shuqun Cheng
Publikováno v:
Acta Materia Medica, Vol 3, Iss 2, Pp 207-225 (2024)
Portal vein tumor thrombosis (PVTT), a severe complication of hepatocellular carcinoma (HCC), markedly influences patient prognosis by fostering a hypercoagulable state. However, its molecular underpinnings remain largely unexplored. This study sheds
Externí odkaz:
https://doaj.org/article/2910c281b0664029b74d06abccded02b